A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

被引：1

作者：

Martin, Thomas ^{[1
]}

Richter, Joshua ^{[2
]}

Vij, Ravi ^{[3
]}

Cole, Craig ^{[4
]}

Atanackovic, Djordje ^{[5
]}

Zonder, Jeffrey ^{[6
]}

Kaufman, Jonathan L. ^{[7
]}

Bensinger, William ^{[8
]}

Dimopoulos, Meletios A. ^{[9
]}

San Miguel, Jesus ^{[10
]}

Zimmerman, Todd ^{[11
]}

Lendvai, Nikoletta ^{[12
]}

Hari, Parameswaran ^{[13
]}

Ocio, Enrique M. ^{[14
]}

Gasparetto, Cristina ^{[15
]}

Kumar, Shaji ^{[16
]}

Hsu, Karl ^{[17
]}

Charpentier, Eric ^{[17
]}

Strickland, Stephen A. ^{[18
]}

Mikhael, Joseph ^{[19
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[3] Washington Univ, St Louis, MO USA

[4] Univ Michigan, Ctr Comprehens Canc, Internal Med Hematol & Oncolgy, Ann Arbor, MI 48109 USA

[5] Huntsman Canc Inst, Salt Lake City, UT USA

[6] Karmanos Canc Inst, Detroit, MI USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[9] Univ Athens, Athens 11528, Greece

[10] Univ Navarra, E-31080 Pamplona, Spain

[11] Univ Chicago, Chicago, IL 60637 USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[13] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[14] Univ Hosp Salamanca, Salamanca, Spain

[15] Duke Univ, Med Ctr, Durham, NC USA

[16] Mayo Clin, Div Hematol, Rochester, MN USA

[17] Sanofi Oncol, Cambridge, MA USA

[18] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[19] Mayo Clin, Scottsdale, AZ USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
Richter, Joshua Ryan
Martin, Thomas G.
Vij, Ravi
Cole, Craig
Atanackovic, Djordje
Zonder, Jeffrey A.
Kaufman, Jonathan L.
Mikhael, Joseph
Bensinger, William
Dimopoulos, Meletios A.
Zimmerman, Todd M.
Lendvai, Nikoletta
Hari, Parameswaran
Ocio, Enrique M.
Gasparetto, Cristina
Kumar, Shaji
Oprea, Corina
Charpentier, Eric
Strickland, Stephen Anthony
Miguel, Jesus San
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] UPDATED DATA FROM A PHASE II DOSE FINDING TRIAL OF SINGLE AGENT ISATUXIMAB (SAR650984, ANTI-CD38 MAB) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Vij, R.
Martin, T.
Richter, J.
Cole, C.
Atanackovic, D.
Zonder, J.
Kaufman, J.
Mikhael, J.
Bensinger, W.
Dimopoulos, M.
Zimmerman, T.
Lendvai, N.
Hari, P.
Ocio, E. M.
Gasparetto, C.
Kumar, S.
Oprea, C.
Charpentier, E.
Strickland, S.
San Miguel, J.
HAEMATOLOGICA, 2016, 101 : 82 - 83
[3] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Mikhael, Joseph
Richter, Joshua
Vij, Ravi
Cole, Craig
Zonder, Jeffrey
Kaufman, Jonathan L.
Bensinger, William
Dimopoulos, Meletios
Lendvai, Nikoletta
Hari, Parameswaran
Ocio, Enrique M.
Gasparetto, Cristina
Kumar, Shaji
Oprea, Corina
Chiron, Marielle
Brillac, Claire
Charpentier, Eric
San-Miguel, Jesus
Martin, Thomas
LEUKEMIA, 2020, 34 (12) : 3298 - 3309
[4] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Joseph Mikhael
Joshua Richter
Ravi Vij
Craig Cole
Jeffrey Zonder
Jonathan L. Kaufman
William Bensinger
Meletios Dimopoulos
Nikoletta Lendvai
Parameswaran Hari
Enrique M. Ocio
Cristina Gasparetto
Shaji Kumar
Corina Oprea
Marielle Chiron
Claire Brillac
Eric Charpentier
Jesús San-Miguel
Thomas Martin
Leukemia, 2020, 34 : 3298 - 3309
[5] A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Martin, Thomas G.
Baz, Rachid
Benson, Don M.
Lendvai, Nikoletta
Campana, Frank
Charpentier, Eric
Vij, Ravi
BLOOD, 2014, 124 (21)
[6] A PHASE IB DOSE ESCALATION TRIAL OF SAR650984 (ANTI-CD-38 MAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Martin, T.
Baz, R.
Benson, D.
Lendvai, N.
Vij, R.
Charpentier, E.
Hsu, K.
HAEMATOLOGICA, 2014, 99 : 114 - 114
[7] A PHASE IB DOSE-ESCALATION TRIAL OF ISATUXIMAB (SAR650984, ANTI-CD38 MAB) PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM RESULTS FROM 2 NEW DOSE COHORTS
Lendvai, N.
Vij, R.
Martin, T. G.
Baz, R.
Campana, F.
Mazuir, F.
Charpentier, E.
Benson, D. M.
HAEMATOLOGICA, 2016, 101 : 84 - 84
[8] A phase lb dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Martin, Thomas G.
Hsu, Karl
Charpentier, Eric
Vij, Ravi
Baz, Rachid C.
Benson, Don M.
Lendvai, Nikoletta
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[9] A PHASE I TRIAL OF SAR650984, A CD38 MONOCLONAL ANTIBODY, IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Martin, T.
Strickland, S.
Glen, M.
Maikhael, J.
Charpentier, E.
Hsu, K.
HAEMATOLOGICA, 2014, 99 : 519 - 519
[10] A phase lb dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.
Vij, Ravi
Lendvai, Nikoletta
Martin, Thomas G.
Baz, Rachid C.
Campana, Frank
Mazuir, Florent
Charpentier, Eric
Benson, Don M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →